THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATION NO.596/2014

Arix Bioscience plc

Arix participates in $70m Harpoon Series C investment round

• Arix’s total interest in Harpoon increases to £20.2 million from £9.4 million

• Uplift of £4.7 million to Arix’s most recent valuation

• Arix invests $8.0 million (£6.1 million¹) to retain a stake of 11.3%

LONDON, 12 November, 2018: Arix Bioscience plc (“Arix”, LSE: ARIX) a global healthcare and life science company supporting medical innovation, today announces that it has invested $8.0 million (£6.1 million¹) in the $70 million (£53 million) Series C financing (“the financing”) of Harpoon Therapeutics, Inc. (“Harpoon”), a clinical-stage immunotherapy company developing a novel class of T cell engagers.

The funding round resulted in a write-up of Arix’s initial investment in Harpoon to £14.1 million, a £4.7 million uplift to Arix’s most recent valuation of £9.4 million². Following the transaction, Arix’s total interest in Harpoon has increased to £20.2 million, including the £6.1 million ($8.0 million) Series C investment.

Arix retains an 11.3% stake on a fully diluted basis and Arix’s Mark Chin will continue to serve on Harpoon’s board of directors.

As announced by Harpoon, new global institutional investors OrbiMed, Cormorant, Ridgeback Capital Investments, Lilly Asia Ventures (LAV) and NS Investment joined the Series C financing round. Additionally to Arix, Harpoon's existing investors MPM Capital, Oncology Impact Fund, New Leaf Venture Partners and Taiho Ventures, LLC also participated in the financing.

Proceeds from the financing will be used to support further advancement of Harpoon’s immunotherapy programs based on its TriTAC (Tri-specific T cell Activating Construct) and ProTriTAC (Protease-activated Tri-specific T Cell Activating Construct) platforms, which are designed to harness the natural power of the body’s immune system to fight cancer and other diseases.

Harpoon’s lead product candidate, HPN424, is currently in a Phase 1 clinical trial for the treatment of metastatic castration-resistant prostate cancer, or mCRPC. Harpoon also plans to initiate Phase 1 clinical trials in for HPN536 (a mesothelin-targeting TriTAC) for the treatment of mesothelin-expressing tumours, and HPN217 (a BCMA-targeting TriTAC) for the treatment of multiple myeloma, in 2019. Additionally, Harpoon expects to advance its first ProTriTAC product candidate into IND-enabling studies in 2019.

ENDS

Enquiries

For more information on Arix, please contact:

Arix Bioscience plc
Charlotte Parry, Head of Investor Relations
+44 (0)20 7290 1072
charlotte@arixbioscience.com

[1] All amounts shown are at an exchange rate of GBP 1.00 : USD 1.31

[2] 30 June 2018 valuation of £5.2 million, plus further £4.2 million invested in July 2018
 

Optimum Strategic Communications
Mary Clark, Supriya Mathur, Hollie Vile
+44 203 714 1787
optimum.arix@optimumcomms.com

Burns McClellan (US Media & IR Enquiries)
Lisa Burns, John Grimaldi, Bill Slattery Jr., Nancie Steinberg
+1 212-213-0006
arix@burnsmc.com

About Arix Bioscience plc

Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.

Arix Bioscience plc is listed on the Main Market of the London Stock Exchange. For further information, please visit www.arixbioscience.com

About Harpoon Therapeutics

Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific

proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct? (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumours and hematologic malignancies. Harpoon recently announced its second technology platform, ProTriTAC, that applies a prodrug concept to TriTAC in order to create T cell engagers that are designed to be preferentially active in the tumour microenvironment.

For more information, please visit www.harpoontx.com.